SEARCH:   Advanced

Blood, 1 May 2006, Vol. 107, No. 9, pp. 3804-3807. Prepublished online as a Blood First Edition Paper on December 29, 2005; DOI 10.1182/blood-2005-09-3827. This Article Full Text (PDF) All Versions of this Article: 2005-09-3827v1 107/9/3804    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Majhail, N. S Articles by Burns, L. J Search for Related Content PubMed PubMed Citation Articles by Majhail, N. S Articles by Burns, L. J Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted September 23, 2005 Accepted December 21, 2005 Comparable results of umbilical cord blood and HLA matched sibling donor hematopoietic stem cell transplant after reduced-intensity preparative regimen for advanced hodgkin's lymphoma Navneet S Majhail, Daniel J Weisdorf, John E Wagner, Todd E Defor, Claudio G Brunstein, and Linda J Burns* Blood and Marrow Transplant Program, Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA * Corresponding author; email: burns019{at}umn.edu. We compared the safety and efficacy of allogeneic stem-cell transplantation (alloSCT) after reduced-intensity conditioning using either unrelated umbilical-cord blood (UCB) or matched-sibling donors (MSD) in 21 high-risk adults with advanced Hodgkin's lymphoma (UCB-9, MSD-12). Both groups were comparable except for younger age in UCB cohort (median 28 vs. 42 years, p=0.02). Neutrophil recovery occurred earlier in MSD group (median 7 vs. 10 days, p=0.02). All patients had sustained donor-engraftment by day +60. Cumulative incidence of acute severe graft-versus-host-disease (33% vs. 33%, p=0.99), chronic graft-versus-host-disease (11% vs. 33%, p=0.24) and 100-day treatment-related mortality (11% vs. 17%, p=0.80) were comparable. With a median followup of 17 and 24 months, the 2-year progression-free survival is 25% (95% CI, 0-55%) for UCB vs. 20% (95% CI, 0-44%) for MSD alloSCT (p=0.67). Our results suggest comparable outcomes for reduced-intensity alloSCT using UCB or MSD source in high-risk adults with advanced Hodgkin's lymphoma. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. A. Rodrigues, G. Sanz, C. G. Brunstein, J. Sanz, J. E. Wagner, M. Renaud, M. de Lima, M. S. Cairo, S. Furst, B. Rio, et al. Analysis of Risk Factors for Outcomes After Unrelated Cord Blood Transplantation in Adults With Lymphoid Malignancies: A Study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation J. Clin. Oncol., January 10, 2009; 27(2): 256 - 263. [Abstract] [Full Text] [PDF] M. E. King and J. M. Rowe Recent Developments in Acute Myelogenous Leukemia Therapy Oncologist, October 1, 2007; 12(suppl_2): 14 - 21. [Abstract] [Full Text] [PDF] J. H. Antin Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2 Hematology, January 1, 2007; 2007(1): 47 - 54. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020